Diabetologie und Stoffwechsel 2021; 16(S 02): S290-S298
DOI: 10.1055/a-1515-8779
DDG-Praxisempfehlung

Adipositas und Diabetes

Jens Aberle
1   Endokrinologie und Diabetologie, Universitäres Adipositas Centrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg
,
Anne Lautenbach
1   Endokrinologie und Diabetologie, Universitäres Adipositas Centrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg
,
Svenja Meyhöfer
2   Institut für Endokrinologie & Diabetes, Universität zu Lübeck, Endokrinologie, Diabetologie und Stoffwechsel, Medizinische Klinik 1, UKSH – Campus Lübeck, Lübeck
,
Sebastian M. Meyhöfer
2   Institut für Endokrinologie & Diabetes, Universität zu Lübeck, Endokrinologie, Diabetologie und Stoffwechsel, Medizinische Klinik 1, UKSH – Campus Lübeck, Lübeck
,
Lars Selig
3   Ernährungsteam/Ernährungsambulanz, Universitätsklinikum Leipzig – AoR, Leipzig
,
Matthias Blüher
4   Klinik und Poliklinik für Endokrinologie und Nephrologie, Universitätsmedizin Leipzig, Leipzig
,
Markus Menzen
5   Abteilung für Innere Medizin, Diabetologie, Gemeinschaftskrankenhaus Bonn, Bonn
› Author Affiliations
Aktualisierungshinweis

Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.

Inhaltliche Änderungen gegenüber der Vorjahresfassung

Änderung 1: ADA Consensus Report Nutrition Therapy for Adults with Diabetes or Prediabetes

Begründung: Ergänzung Ernährungsempfehlungen für Patienten mit Diabetes mellitus/Prädiabetes

Stützende Quellenangabe: [10]

Änderung 2: STEP-1 Studie

Begründung: Aktuelle Phase-3-Studienergebnisse

Stützende Quellenangabe: [20]

Änderung 3: SURPASS-1 Studie

Begründung: Aktuelle Phase-3-Studienergebnisse

Stützende Quellenangabe: [25]



Publication History

Article published online:
21 October 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Lindström J, Louheranta A, Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236
  • 2 Knowler WC, Barrett-Connor E, Fowler SE. et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346: 393-403
  • 3 Lean MEJ, Powrie JK, Anderson AS. et al. Obesity, Weight Loss and Prognosis in Type 2 Diabetes. Diabet Med 1990; 7: 228-233
  • 4 Williamson DF, Thompson TJ, Thun M. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504
  • 5 Wing RR, Bahnson JL, Bray GA. et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
  • 6 Eeg-Olofsson K, Cederholm J, Nilsson PM. et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13,087 patients. Diabetologia 2009; 52: 65-73
  • 7 Buse JB, Wexler DJ, Tsapas A. et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-493
  • 8 Wang Z, Hoy WE. Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 2004; 58: 888-893
  • 9 Pischon T, Boeing H, Hoffmann K. et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120
  • 10 Evert AB, Dennison M, Gardner CD. et al. Nutrition therapy for adults with diabetes or prediabetes: A consensus report. Diabetes Care 2019; 42: 731-754
  • 11 Reynolds AN, Akerman AP, Mann J. Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses. PLoS Med 2020; 17: e1003053
  • 12 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapy of Type 2 Diabetes. Exp Clin Endocrinol Diabetes 2019; 127: S73-S92
  • 13 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551
  • 14 Gregg EW, Chen H, Wagenknecht LE. et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA – J Am Med Assoc 2012; 308: 2489-2496
  • 15 Nationale VersorgungsLeitlinie (NVL) Typ-- Diabetes. 1. Auflage.
  • 16 Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: A systematic review of the literature. Obes Rev 2006; 7: 183-200
  • 17 Piercy KL, Troiano RP, Ballard RM. et al. The Physical Activity Guidelines for Americans. JAMA 2018; 320: 2020
  • 18 Vilsbøll T, Christensen M, Junker AE. et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344
  • 19 Pi-Sunyer X, Astrup A, Fujioka K. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22
  • 20 Wilding JPH, Batterham RL, Calanna S. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384: 989-1002
  • 21 Muscelli E, Mari A, Casolaro A. et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348
  • 22 Liu C, Li C, Cai X. et al. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. Bioorg Chem 2021; 106
  • 23 Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34
  • 24 Alvarez E, Martínez MD, Roncero I. et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005; 92: 798-806
  • 25 Rosenstock J, Wysham C, Frías JP. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;
  • 26 Rubino F, Nathan DM, Eckel RH. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care 2016; 39: 861-877
  • 27 S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. Version 2.3 (Februar 2018)
  • 28 Perioperative Safety in the Longitudinal Assessment of Bariatric Surgery. N Engl J Med 2009; 361: 445-454
  • 29 Birkmeyer NJO, Dimick JB, Share D. et al. Hospital complication rates with bariatric surgery in Michigan. JAMA – J Am Med Assoc 2010; 304: 435-442
  • 30 Aberle J, Reining F, Dannheim V. et al. Metformin after bariatric surgery – An acid problem. Exp Clin Endocrinol Diabetes 2012; 120: 152-153